<DOC>
	<DOCNO>NCT02585843</DOCNO>
	<brief_summary>This prospective , single-center , double-blind randomize placebo control trial evaluation 7-day 100mg daily dose spironolactone weight loss resolution sign symptom congestion outpatient acute decompensated heart failure ( ADHF ) . Patients respond current loop diuretic consider study . Mineralocorticoid receptor antagonist ( MRAs ) recommend standard care management heart failure ( HF ) patient . However , recommend dos MRAs ( spironolactone 25mg/daily eplerenone 50mg/daily ) impact sign symptom volume overload . Therefore , propose study aim show impact outpatient regimen improve diuresis possible reduction hospitalization diuretic management HF patient sign symptom congestion .</brief_summary>
	<brief_title>Mineralocorticoid Receptor Antagonists ( MRA ) Heart Failure ( HF ) Loop Diuretic Resistance</brief_title>
	<detailed_description>The incidence prevalence heart failure ( HF ) rise 5 million Americans suffer syndrome . Hospitalization rate acute decompensated heart failure ( ADHF ) also remarkably high , exceed 1 million admission per year . Congestion main cause hospitalization ADHF . Loop diuretic main therapy decongestion , often adequate since many patient ADHF develop `` loop diuretic resistance '' . These patient require hospitalization intravenous diuretic advanced decongestion therapy . Thus , novel decongestion therapy need decrease hospital admission rate subsequent complication multiple hospitalization . Hyperaldosteronism , pivotal pathogenic factor HF , also contribute loop diuretic resistance . Attempts normalization circulatory aldosterone mineralocorticoid receptor antagonist ( MRAs ) , mainly spironolactone , show decrease mortality HF patient reduce left ventricular ejection fraction ( LVEF ) . Moreover , MRAs significantly decrease rate rehospitalization HF preserve reduced LVEF . The dose spironolactone trial 25mg daily . However , dose increase natriuresis ( urinary sodium excretion ) . Natriuresis achieve high dos MRAs . Therefore , primary aim study examine efficacy 7-day 100mg daily spironolactone weight loss resolution sign symptom congestion patient age 60 year ADHF loop diuretic resistance .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Mineralocorticoids</mesh_term>
	<mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
	<criteria>History heart failure either reduced preserved ejection fraction 3 month Patients New York Heart Association ( NYHA ) class II IV heart failure symptom , least one worsen symptom ( Dyspnea exertion , shortness breath , orthopnea , early satiety ) one sign congestion ( pulmonary rale , elevate jugular venous pressure10cmHg , peripheral edema ascites ) Decision primary cardiologist heart failure ( HF ) specialist increase home diuretic dose Stable treatment betablockers 1 month unless contraindicate ( i.e . intolerance , bradycardia ) specify primary cardiologist/HF provider Stable treatment angiotensin convert enzyme1 ( ACE1 ) angiotensin receptor blocker ( ARB ) 1 month Spironolactone dose 25mg eplerenone 50mg per day Daily furosemide furosemide equivalent dose 80mg great Serum potassium concentration 4.5 mmol/L 5.0 mmol/L potassium supplement Estimated Glomerular Filtration Rate ( eGFR ) Modification Diet Renal Disease ( MDRD ) equation 40 ml/min/1.73 Inability complete inform consent form Allergy intolerance spironolactone Systolic blood pressure &lt; 100 mmHg Patient need hospitalization per cardiologist decision Current inotrope dependency Current mechanical circulatory support Acute coronary syndrome unstable angina within past 4 week History cardiac transplant Obstructive cardiac valvular disease Primary hypertrophic cardiomyopathy , infiltrative cardiomyopathy Significant ventricular arrhythmia necessitate defibrillator therapy within past 14 day Atrioventricular conduction abnormality great firstdegree block Primary liver disease result cirrhosis abnormal liver function test ( transaminase alkaline phosphatase level 3 time upper limit normal Acute malignancy Active infection require antimicrobial treatment ( Suppression antimicrobial chronic infection exempt )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Mineralocorticoid receptor antagonist</keyword>
	<keyword>Loop diuretic resistance</keyword>
</DOC>